You are here
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
National Institute for Health and Clinical Excellence (NICE).
National Institute for Health and Clinical Excellence (NICE); 2012 Dec. 45 p. (Technology appraisal guidance; no. 269).
Conclusions of the Review
The manufacturer's search of the published cost-effectiveness literature describing the use of vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation positive malignant melanoma did not identify any relevant cost-effectiveness studies. The ERG is satisfied with the manufacturer's search strategy and is reasonably confident that the manufacturer did not miss any relevant published articles.